New schizophrenia drug shows promise in early trial

NCT ID NCT06179108

Completed Disease control Sponsor: LB Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called LB-102 in 359 adults with acute schizophrenia. Participants received either LB-102 or a placebo for 28 days. The goal was to see if LB-102 reduces symptoms like hallucinations and confusion better than a placebo. The trial is now complete, and results will show if LB-102 is safe and effective enough to move to larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LB-102 (a drug that blocks certain brain receptors linked to schizophrenia symptoms)
What this could lead to: If successful, LB-102 could offer a new treatment option for acute schizophrenia, potentially improving symptoms like hallucinations and delusions.
What could go wrong: This is an early Phase 2 trial with only 359 people. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Behavioral Clinical Research, Inc.

Hollywood, Florida, 33021, United States
CelExel CNS

Garden Grove, California, 92845, United States
CelExel Clinical Innovations

Bellflower, California, 90706, United States
CenExel ACMR

Atlanta, Georgia, 30331, United States
CenExel CBH

Gaithersburg, Maryland, 20877, United States
CenExel CIT Riverside

Riverside, California, 92506, United States
CenExel HRI

Berlin, New Jersey, 08009, United States
CenExel RCA

Hollywood, Florida, 33024, United States
CenExel iResearch

Decatur, Georgia, 30030, United States
Community Clinical Research

Austin, Texas, 78754, United States
InSite Clinical Research

DeSoto, Texas, 75115, United States
Midwest Clinical Research Center

Dayton, Ohio, 45417, United States
NRC Research Institute

Santa Ana, California, 92705, United States
Neuro-Behavioral Clinical Research

North Canton, Ohio, 44720, United States
Pillar Clinical Research

Bentonville, Arkansas, 72712, United States
Pillar Clinical Research

Chicago, Illinois, 60641, United States
Pillar Clinical Research

Richardson, Texas, 75080, United States
ProScience Research Group

Culver City, California, 90230, United States
Richmond Behavioral Associates

Staten Island, New York, 10314, United States
Segal Institute for Clinical Research

Miami Lakes, Florida, 33016, United States
Synergy Research

Lemon Grove, California, 91945, United States
Synexus

Cerritos, California, 90703, United States
Uptown Research Institute

Chicago, Illinois, 60640, United States
Woodland Internation Research Group

Little Rock, Arkansas, 72211, United States
Woodland Research Northwest

Rogers, Arkansas, 72758, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.